MA41014A - Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique - Google Patents

Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique

Info

Publication number
MA41014A
MA41014A MA041014A MA41014A MA41014A MA 41014 A MA41014 A MA 41014A MA 041014 A MA041014 A MA 041014A MA 41014 A MA41014 A MA 41014A MA 41014 A MA41014 A MA 41014A
Authority
MA
Morocco
Prior art keywords
arylmethyl
carboxamides
het
heteroaryl
kallikrein inhibitors
Prior art date
Application number
MA041014A
Other languages
English (en)
Other versions
MA41014B1 (fr
Inventor
Rebecca Louise Davie
Hannah Joy Edwards
David Michael Evans
Simon Teanby Hodgson
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52349552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41014(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of MA41014A publication Critical patent/MA41014A/fr
Publication of MA41014B1 publication Critical patent/MA41014B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA41014A 2014-11-27 2015-11-26 Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique MA41014B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1421083.5A GB201421083D0 (en) 2014-11-27 2014-11-27 Enzyme inhibitors
EP15804210.1A EP3224256B1 (fr) 2014-11-27 2015-11-26 Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique
PCT/GB2015/053615 WO2016083820A1 (fr) 2014-11-27 2015-11-26 Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique

Publications (2)

Publication Number Publication Date
MA41014A true MA41014A (fr) 2017-10-04
MA41014B1 MA41014B1 (fr) 2019-09-30

Family

ID=52349552

Family Applications (3)

Application Number Title Priority Date Filing Date
MA52063A MA52063B1 (fr) 2014-11-27 2015-11-26 Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA47217A MA47217B1 (fr) 2014-11-27 2015-11-26 Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA41014A MA41014B1 (fr) 2014-11-27 2015-11-26 Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA52063A MA52063B1 (fr) 2014-11-27 2015-11-26 Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA47217A MA47217B1 (fr) 2014-11-27 2015-11-26 Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique

Country Status (41)

Country Link
US (7) US10364238B2 (fr)
EP (4) EP4039681A1 (fr)
JP (5) JP6653702B2 (fr)
KR (2) KR102267623B1 (fr)
CN (2) CN110577519A (fr)
AR (2) AR102850A1 (fr)
AU (2) AU2015352193B2 (fr)
BR (1) BR112017010882B8 (fr)
CA (1) CA2967894C (fr)
CL (1) CL2017001362A1 (fr)
CO (1) CO2017006230A2 (fr)
CY (3) CY1122255T1 (fr)
DK (3) DK3224256T3 (fr)
EC (1) ECSP17039127A (fr)
ES (3) ES2908303T3 (fr)
FI (1) FIC20265004I1 (fr)
FR (1) FR26C1004I1 (fr)
GB (1) GB201421083D0 (fr)
HR (3) HRP20191524T1 (fr)
HU (3) HUE053317T2 (fr)
IL (2) IL278182B (fr)
LT (4) LT3556752T (fr)
MA (3) MA52063B1 (fr)
MD (3) MD3224256T2 (fr)
ME (1) ME03514B (fr)
MX (2) MX2020013038A (fr)
MY (1) MY176853A (fr)
NO (1) NO2026004I1 (fr)
NZ (1) NZ731945A (fr)
PH (1) PH12017500901B1 (fr)
PL (3) PL3556752T3 (fr)
PT (3) PT3556752T (fr)
RS (3) RS61497B1 (fr)
RU (1) RU2707870C2 (fr)
SG (2) SG11201703988PA (fr)
SI (3) SI3567037T1 (fr)
SM (3) SMT202200107T1 (fr)
TW (2) TWI741377B (fr)
UA (1) UA123087C2 (fr)
WO (1) WO2016083820A1 (fr)
ZA (1) ZA201907052B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
EP4019022B1 (fr) 2015-10-01 2024-01-31 BioCryst Pharmaceuticals, Inc. Inhibiteurs de la kallicréine plasmatique humaine
RS60600B1 (sr) * 2016-05-31 2020-08-31 Kalvista Pharmaceuticals Ltd Derivati pirazola kao inhibitori kalikreina plazme
GB201609519D0 (en) * 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
US11168080B2 (en) 2017-04-26 2021-11-09 Mitobridge, Inc. Dynamin-1-like protein inhibitors
GB201719882D0 (en) * 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
WO2019106359A1 (fr) * 2017-11-29 2019-06-06 Kalvista Pharmaceuticals Limited Inhibiteurs d'enzymes
IL274557B2 (en) 2017-11-29 2024-09-01 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibitor
GB201719881D0 (en) * 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
KR20200143376A (ko) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
EP3886854A4 (fr) 2018-11-30 2022-07-06 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
GB201910125D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
ES2987744T3 (es) 2019-09-18 2024-11-18 Takeda Pharmaceuticals Co Inhibidores de calicreína plasmática y usos de los mismos
WO2021055589A1 (fr) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Inhibiteurs hétéroaryles de la kallicréine plasmatique
CN113004286B (zh) * 2019-12-20 2022-08-12 成都康弘药业集团股份有限公司 作为血浆激肽释放酶抑制剂的三环类化合物及其用途
TW202144331A (zh) * 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
JP7245397B2 (ja) * 2020-03-04 2023-03-23 メッドシャイン ディスカバリー インコーポレイテッド 複素環化合物
BR112022025528A2 (pt) 2020-06-16 2023-01-17 Merck Sharp & Dohme Llc Composto, composição farmacêutica, e, métodos para tratar atividade visual prejudicada, retinopatia diabética, edema macular diabético, oclusão de veia retinal, angioedema hereditário, diabete, pancreatite, hemorragia cerebral, nefropatia, cardiomiopatia, neuropatia, doença intestinal inflamatória, artrite, inflamação, choque séptico, hipotensão, câncer, síndrome da angústia respiratória do adulto, coagulação intravascular disseminada, coagulação sanguínea durante cirurgia de desvio cardiopulmonar ou hemorragia do pós-operatório de cirurgia e para tratar uveíte, uveíte posterior, edema macular relacionado com a idade úmido
WO2022010828A1 (fr) 2020-07-10 2022-01-13 Merck Sharp & Dohme Corp. Inhibiteurs de la kallicréine plasmatique
TW202228686A (zh) 2020-10-15 2022-08-01 英商卡爾維斯塔製藥有限公司 血管性水腫之治療
WO2022084693A1 (fr) 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Traitements de l'oedème de quincke
WO2022172006A1 (fr) 2021-02-09 2022-08-18 Kalvista Pharmaceuticals Limited Traitements de l'angio-oedème héréditaire
WO2023002219A1 (fr) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Traitements de l'angio-oedème héréditaire
WO2023185634A1 (fr) * 2022-03-30 2023-10-05 南京明德新药研发有限公司 Composé hétérocyclique utilisé comme inhibiteur de la kallicréine plasmatique
IL316435A (en) 2022-04-27 2024-12-01 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitor formulations
IL318607A (en) * 2022-07-29 2025-03-01 Rezolute Inc Plasma kallikrein inhibitors
EP4673437A1 (fr) 2023-02-27 2026-01-07 Kalvista Pharmaceuticals Limited Nouvelle forme solide d'un inhibiteur de la kallicréine plasmatique
AU2024307587A1 (en) 2023-06-30 2026-02-19 Longwood Pharmaceuticals (Hangzhou) Co., Ltd Heteroaromatic formamide compounds and uses thereof in medicine
WO2025153806A1 (fr) 2024-01-15 2025-07-24 Kalvista Pharmaceuticals Limited Procédés de détermination de l'activité amidolytique
WO2025172693A1 (fr) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Sebetralstat oral pour le traitement d'un épisode d'angio-œdème héréditaire
WO2025172692A1 (fr) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Sebetralstat à administrer par voie orale pour le traitement d'une attaque d'angioedème héréditaire

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US7101878B1 (en) 1998-08-20 2006-09-05 Agouron Pharmaceuticals, Inc. Non-peptide GNRH agents, methods and intermediates for their preparation
PT1169038E (pt) 1999-04-15 2012-10-26 Bristol Myers Squibb Co Inibidores cíclicos da proteína tirosina cinase
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
DE60235114D1 (de) 2001-11-01 2010-03-04 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
AU2003230829B8 (en) 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
EP1426364A1 (fr) 2002-12-04 2004-06-09 Aventis Pharma Deutschland GmbH Dérivés d'imidazole comme inhibiteurs du facteur Xa
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
WO2004069792A2 (fr) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Amides derives quinoliniques modulant le recepteur vr1 vanilloide
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
TW200526588A (en) * 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
GB0403155D0 (en) 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
EP1568698A1 (fr) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Dérivés de pyrrole en tant qu'inhibiteurs du facteur xa
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
ES2367312T3 (es) 2004-09-03 2011-11-02 Yuhan Corporation DERIVADOS DE PIRROLO [3,2-c] PIRIDINA Y PROCESOS PARA LA PREPARACIÓN DE LOS MISMOS.
US8841259B2 (en) 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
KR101142363B1 (ko) 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
KR20080032188A (ko) 2005-07-14 2008-04-14 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
WO2007011328A1 (fr) 2005-07-14 2007-01-25 Jackson Kenneth A Procédé d’inhibition d’aiguille hypodermique après utilisation
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
GB0606876D0 (en) 2006-04-05 2006-05-17 Glaxo Group Ltd Compounds
US20070258976A1 (en) 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
US7718693B2 (en) 2006-07-06 2010-05-18 Glaxo Group Limited Receptor antagonists and their methods of use
AU2007281220B2 (en) 2006-07-31 2013-08-15 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
PT2439205E (pt) 2006-12-29 2015-07-16 Abbvie Deutschland Compostos de carboxamida e seus usos como inibidores de calpaína
WO2008091692A2 (fr) 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Procédés de diagnostic, de traitement et de prévention de la perméabilité vasculaire accrue
CA2680173A1 (fr) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Inhibiteurs de metalloprotease contenant une fraction heterocyclique
SG179437A1 (en) 2007-03-30 2012-04-27 Sanofi Aventis Pyrimidine hydrazide compounds as pgds inhibitors
CN101679291A (zh) 2007-04-03 2010-03-24 葛兰素集团有限公司 作为p2x7调节剂的咪唑烷甲酰胺衍生物
CL2008002172A1 (es) 2007-07-26 2008-11-21 Syngenta Participations Ag Compuestos derivados de pirazol-etiloxiamidas; compuestos intermediarios; metodo para controlar o prevenir la infestacion de plantas utiles por parte de microorganismos fitopatogenos; y composicion para controlar y proteger contra microorganismos fitopatogenos.
WO2009026407A1 (fr) 2007-08-22 2009-02-26 Allergan, Inc. Composés pyrroliques ayant une activité agoniste de récepteur de sphingosine-1-phosphate ou une activité biologique antagoniste
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009083553A1 (fr) 2007-12-31 2009-07-09 Rheoscience A/S Composés azines en tant qu'activateurs de glucokinase
WO2009097141A1 (fr) 2008-01-31 2009-08-06 Joslin Diabetes Center Méthodes de traitement de troubles associés à la kallikréine
WO2009106980A2 (fr) 2008-02-29 2009-09-03 Pfizer Inc. Dérivés d'indazole
WO2009114677A1 (fr) 2008-03-13 2009-09-17 Bristol-Myers Squibb Company Dérivés de la pyridazine inhibiteurs du facteur xia
CA2730078A1 (fr) 2008-07-08 2010-01-14 Daiichi Sankyo Company, Limited Compose a heterocycle aromatique contenant de l'azote
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
JP2013515000A (ja) 2009-12-18 2013-05-02 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬のプロドラッグ
JP2011157349A (ja) 2010-01-07 2011-08-18 Daiichi Sankyo Co Ltd 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物
JP5709902B2 (ja) 2010-01-28 2015-04-30 ザ メディシンズ カンパニー （ライプツィヒ） ゲーエムベーハー トリプシン様セリンプロテアーゼ阻害剤、ならびにその調製および使用
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
ES2483802T3 (es) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Inhibidores de serina proteasa
EP2595986A2 (fr) 2010-07-14 2013-05-29 Addex Pharma SA Nouveaux dérivés de 2-amino-4-pyrazolyl-thiazole et leur utilisation en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate
US9290485B2 (en) * 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
EP2458315B1 (fr) 2010-11-25 2017-01-04 Balcke-Dürr GmbH Echangeur thermique régénératif doté d'un joint de rotor forcé
US8691861B2 (en) 2011-04-13 2014-04-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2012174362A1 (fr) 2011-06-17 2012-12-20 Research Triangle Institute Dérivés de pyrazole utilisés en tant qu'antagonistes du récepteur de type 1 des cannabinoïdes
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
WO2013049096A1 (fr) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Composés de pyrrolinone-carboxamide utiles en tant qu'inhibiteurs de lipase endothéliale
WO2013048982A1 (fr) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Composés de pyrrolinone-carboxamide utiles en tant qu'inhibiteurs de lipase endothéliale
WO2013111108A1 (fr) 2012-01-27 2013-08-01 Novartis Ag Dérivés hétéroarylcarboxamide à 5 chaînons comme inhibiteurs de la kallikréine plasmatique
EP2807156A1 (fr) 2012-01-27 2014-12-03 Novartis AG Dérivés d'aminopyridine utilisés en tant qu'inhibiteurs de la kallicréine plasmatique
WO2013120104A2 (fr) 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, leurs compositions et utilisations
WO2013130603A1 (fr) 2012-02-27 2013-09-06 Board Of Regents, The University Of Texas System Ganglioside gd2 en tant que marqueur et cible sur des cellules souches cancéreuses
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
AU2014204889A1 (en) 2013-01-08 2015-06-11 European Molecular Biology Laboratory Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
IL273688B2 (en) 2013-01-20 2024-12-01 Dyax Corp Evaluation and treatment of bradykinin-mediated disorders
ES2853483T3 (es) 2013-03-15 2021-09-16 Verseon Int Corporation Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa
HUE034829T2 (en) 2013-05-23 2018-03-28 Kalvista Pharmaceuticals Ltd Heterocyclic derivatives
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
HUE14755117T2 (hu) 2013-08-14 2018-12-28 Kalvista Pharmaceuticals Ltd Plazma-kallikrein inhibitorok
WO2015103317A1 (fr) 2013-12-30 2015-07-09 Lifesci Pharmaceuticals, Inc. Composés inhibiteurs thérapeutiques
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
PL3828173T3 (pl) 2014-03-07 2022-12-19 Biocryst Pharmaceuticals, Inc. Podstawiane pirazole jako inhibitory ludzkiej kalikreiny osoczowej
WO2015171527A1 (fr) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Pyrazolopyridine, pyrazolopyrimidine et composés apparentés
WO2015171526A2 (fr) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Composés de pyrazolopyridine tricycliques
MX381342B (es) 2014-07-16 2025-03-12 Lifesci Pharmaceuticals Inc Compuestos terapeuticos inhibidores.
CA2959026C (fr) 2014-08-22 2023-10-24 Biocryst Pharmaceuticals, Inc. Compositions et utilisations de derives d'amidine
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
US10532995B2 (en) 2015-02-27 2020-01-14 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
CA2991171A1 (fr) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc. Composes inhibiteurs therapeutiques
EP3317241A4 (fr) 2015-07-01 2019-01-23 Lifesci Pharmaceuticals, Inc. Composés inhibiteurs thérapeutiques
EP3368524B1 (fr) 2015-10-27 2021-08-18 Boehringer Ingelheim International GmbH Utilisation de dérivés hétéroarylcarboxamides comme inhibiteurs de la kallicréine plasmatique
WO2017072020A1 (fr) 2015-10-27 2017-05-04 Boehringer Ingelheim International Gmbh Utilisation de dérivés hétéroarylcarboxamides comme inhibiteurs de la kallicréine plasmatique
RS60600B1 (sr) 2016-05-31 2020-08-31 Kalvista Pharmaceuticals Ltd Derivati pirazola kao inhibitori kalikreina plazme
GB201609519D0 (en) 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
WO2018011628A1 (fr) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Composés inhibiteurs thérapeutiques
WO2019106359A1 (fr) 2017-11-29 2019-06-06 Kalvista Pharmaceuticals Limited Inhibiteurs d'enzymes
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201719882D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof

Also Published As

Publication number Publication date
MX378283B (es) 2025-03-10
JP6995101B2 (ja) 2022-01-14
JP2025000918A (ja) 2025-01-07
MD3556752T2 (ro) 2022-07-31
LT3556752T (lt) 2022-03-10
HUE047425T2 (hu) 2020-04-28
IL278182B (en) 2022-09-01
JP2022180520A (ja) 2022-12-06
HK1244268A1 (en) 2018-08-03
PT3567037T (pt) 2021-02-23
KR20170090451A (ko) 2017-08-07
PH12017500901B1 (en) 2022-04-27
US10611758B2 (en) 2020-04-07
MX2017006823A (es) 2017-09-27
BR112017010882A2 (pt) 2017-12-26
MA47217B1 (fr) 2021-04-30
TWI686383B (zh) 2020-03-01
LT3567037T (lt) 2021-02-25
CN107108576A (zh) 2017-08-29
US10364238B2 (en) 2019-07-30
AR121273A2 (es) 2022-05-04
US20180319782A1 (en) 2018-11-08
SG11201703988PA (en) 2017-06-29
EP3224256B1 (fr) 2019-07-03
RU2017122364A3 (fr) 2019-06-19
US20200361923A1 (en) 2020-11-19
HRP20220314T1 (hr) 2022-05-13
KR102267623B1 (ko) 2021-06-18
AR102850A1 (es) 2017-03-29
NO2026004I1 (no) 2026-01-16
UA123087C2 (uk) 2021-02-17
BR112017010882B1 (pt) 2023-10-31
SMT202100112T1 (it) 2021-05-07
TWI741377B (zh) 2021-10-01
ES2858082T3 (es) 2021-09-29
FR26C1004I1 (fr) 2026-03-06
BR112017010882B8 (pt) 2023-11-14
MD3567037T2 (ro) 2021-05-31
DK3556752T3 (da) 2022-03-07
AU2019240616A1 (en) 2019-10-17
ECSP17039127A (es) 2017-12-01
CY1125214T1 (el) 2023-06-09
RS59395B1 (sr) 2019-11-29
RS63155B1 (sr) 2022-05-31
MD3224256T2 (ro) 2019-12-31
US11198691B2 (en) 2021-12-14
PL3556752T3 (pl) 2022-05-02
PT3556752T (pt) 2022-04-14
EP3556752A1 (fr) 2019-10-23
PL3567037T3 (pl) 2021-06-14
CA2967894A1 (fr) 2016-06-02
CN110577519A (zh) 2019-12-17
CY1122255T1 (el) 2020-11-25
IL278182A (en) 2020-11-30
IL252287A0 (en) 2017-07-31
HRP20210350T1 (hr) 2021-04-16
ZA201907052B (en) 2025-01-29
SI3224256T1 (sl) 2019-12-31
US20220289729A1 (en) 2022-09-15
US11084809B2 (en) 2021-08-10
WO2016083820A1 (fr) 2016-06-02
PT3224256T (pt) 2019-09-23
JP7148683B2 (ja) 2022-10-05
NZ770256A (en) 2021-11-26
JP6653702B2 (ja) 2020-02-26
PH12017500901A1 (en) 2017-12-18
LT3224256T (lt) 2019-09-25
CN107108576B (zh) 2020-03-10
US20190300517A1 (en) 2019-10-03
JP2017535568A (ja) 2017-11-30
RU2707870C2 (ru) 2019-12-02
HUE057647T2 (hu) 2022-05-28
MA52063A (fr) 2021-05-26
DK3224256T3 (da) 2019-09-23
LTPA2026502I1 (fr) 2026-02-10
KR102496404B1 (ko) 2023-02-06
TW201625548A (zh) 2016-07-16
GB201421083D0 (en) 2015-01-14
TW202026285A (zh) 2020-07-16
ME03514B (fr) 2020-04-20
EP3224256A1 (fr) 2017-10-04
JP2020033357A (ja) 2020-03-05
ES2908303T3 (es) 2022-04-28
FIC20265004I1 (fi) 2026-01-13
RU2019131174A (ru) 2019-10-10
US20190330200A1 (en) 2019-10-31
RS61497B1 (sr) 2021-03-31
CO2017006230A2 (es) 2017-09-11
NZ731945A (en) 2021-07-30
US20250074903A1 (en) 2025-03-06
PL3224256T3 (pl) 2020-01-31
MA47217A (fr) 2019-11-13
KR20210075227A (ko) 2021-06-22
MY176853A (en) 2020-08-24
DK3567037T3 (da) 2021-02-08
AU2019240616B2 (en) 2021-07-29
US20200199116A1 (en) 2020-06-25
ES2745815T3 (es) 2020-03-03
SMT201900497T1 (it) 2019-11-13
AU2015352193B2 (en) 2019-10-10
SI3556752T1 (sl) 2022-05-31
EP3556752B1 (fr) 2022-01-05
SG10201907819WA (en) 2019-09-27
CL2017001362A1 (es) 2018-02-09
CA2967894C (fr) 2024-01-30
MA41014B1 (fr) 2019-09-30
EP3567037A1 (fr) 2019-11-13
CY1124046T1 (el) 2022-05-27
MA52063B1 (fr) 2022-01-31
US11001578B2 (en) 2021-05-11
IL252287B (en) 2020-11-30
HRP20191524T1 (hr) 2019-11-29
MX2020013038A (es) 2022-12-09
AU2015352193A1 (en) 2017-06-08
EP3567037B1 (fr) 2020-12-23
HUE053317T2 (hu) 2021-06-28
RU2017122364A (ru) 2018-12-27
SI3567037T1 (sl) 2021-04-30
SMT202200107T1 (it) 2022-05-12
EP4039681A1 (fr) 2022-08-10
JP2021185138A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
FR26C1004I1 (fr) Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique
IL287517A (en) Benzimidazole compounds as c-kit inhibitors
LT3371190T (lt) Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
LT3303334T (lt) Tirozinkinazės inhibitoriai
EP3347008A4 (fr) Inhibiteurs de bêta-lactamases
MA53944A (fr) Inhibiteurs de la glycosidase
PT3154989T (pt) Inibidores de beta-lactamase
ME03485B (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
EP3313828A4 (fr) Inhibiteurs de métallo-bêta-lactamases
CL2016002638A1 (es) Nuevos inhibidores de la nitrificación
PL3224255T3 (pl) Związki n-((het)arylometylo)heteroarylokarboksyamidów jako inhibitory kalikreiny osoczowej
DK3458460T3 (da) Imidazoler som histondemethylase-inhibitorer
EP3394068A4 (fr) Inhibiteurs de tdo2
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
ECSP17015682A (es) Inhibidores cristalinos de bace
TH1601003823B (th) ระบบจัดการงาน